Key facts
- It has raised $336.6M across 1 recorded rounds; the latest was Later Stage VC (Series B) ($225.0M) in May 2024.
- Notable investors include RA Capital Management, Blackstone, Cormorant Asset Management, Soleus Capital, CAM Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for AltruBio
Funding rounds
1 roundsAbout AltruBio
Developer of first-in-class immune-modulators to target diseases of the immune system. The company has clinically validated a first-in-class immune checkpoint regulator mechanism to selectively target unwanted (thymocytes - cells) T-cells with its antibodies, enhancing PSGL-1's natural immune function to downregulate late-stage chronically activated T-cells, enabling a world-class global team to bring a breadth of expertise in immunology and drug development to bring their biologic treatments to patients.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2000
- Employees
- 30
- Website
- altrubio.com/
- Ownership
- Privately Held (backing)
AltruBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AltruBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AltruBio in its N-PORT filings yet. We sweep new filings monthly.